Thank You for 2025 | Growing Together with Celnovte Worldwide

2026-01-03

By celnovte

Share to:

Dear Valued Partners,

As 2025 comes to a close, we would like to extend our sincere thanks to you for your trust, collaboration, and continued partnership with Celnovte.

This year, together we achieved meaningful progress—from new automated IHC and ISH platforms, expanded FDA-cleared and EU-certified product portfolios, to broader global market access. Today, Celnovte solutions are installed in 800+ laboratories, serving 1,500+ hospitals across 35+ countries and regions—a milestone made possible by your local expertise and dedication.

Driven by strong R&D, we advanced ADC companion diagnostics, expanded our Super-ISH™ and antibody platforms, earned 41 NordiQC recognition, and contributed to 200+ high-impact scientific publications, amplifying the voice of pathology innovation on the global stage.

Looking ahead to 2026, we remain committed to supporting you with reliable products, continuous innovation, strong technical service, and long-term collaboration as we jointly advance precision pathology worldwide.

Thank you for walking this journey with us. We look forward to achieving new milestones together in 2026.